Kilbac
Generic Name
Ceftriaxone 750 mg Injection
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| kilbac 750 mg injection | ৳ 125.00 | N/A |
Description
Overview of the medicine
Ceftriaxone is a broad-spectrum antibiotic from the cephalosporin class, used to treat a wide range of bacterial infections including severe ones.
Uses & Indications
Dosage
Adults
Usual adult dose is 1-2 g IV/IM once daily, depending on the severity and type of infection. For this strength, it's typically used as 750 mg - 1.5 g IV/IM once daily.
Elderly
No specific dose adjustment is generally necessary unless there is severe renal or hepatic impairment.
Renal_impairment
No dose adjustment for mild to moderate renal impairment. For severe impairment (creatinine clearance <10 mL/min), do not exceed 2 g/day.
How to Take
Kilbac 750 mg Injection is administered by deep intramuscular (IM) injection or slow intravenous (IV) injection/infusion. It must be reconstituted with an appropriate diluent before use. IV administration should be over 2-4 minutes (for bolus) or 30 minutes (for infusion).
Mechanism of Action
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bacterial cell lysis and death.
Pharmacokinetics
Onset
Peak plasma concentrations reached within 2-3 hours after IM administration; clinical effects typically within 30 minutes to 1 hour.
Excretion
Approximately 50-60% excreted unchanged via the kidneys, and 40-50% via bile and feces.
Half life
6-9 hours (prolonged in neonates and elderly).
Absorption
Rapid and complete absorption after intramuscular (IM) injection, with high bioavailability.
Metabolism
Partially metabolized in the liver to inactive metabolites.
Side Effects
Contraindications
- Known hypersensitivity to ceftriaxone, any other cephalosporins, or any component of the formulation.
- Neonates (≤28 days) with hyperbilirubinemia, particularly premature neonates.
- Concomitant intravenous calcium administration in neonates.
Drug Interactions
Aminoglycosides
Synergistic effect against some bacteria, but solutions should not be mixed due to physical incompatibility.
Calcium-containing solutions
Concomitant use of ceftriaxone with intravenous calcium-containing solutions is contraindicated in neonates. In other age groups, a time interval should be observed between ceftriaxone and calcium administration.
Loop diuretics (e.g., Furosemide)
May increase the risk of nephrotoxicity with high doses of cephalosporins.
Oral anticoagulants (e.g., Warfarin)
May increase the anticoagulant effect and risk of bleeding. Close monitoring of coagulation parameters is advised.
Storage
Store the dry powder below 30°C, protected from light and moisture. After reconstitution, the solution should be used immediately. If not used immediately, store refrigerated (2-8°C) and use within 24 hours (for IV) or 6 hours (for IM). Do not freeze.
Overdose
In case of overdose, symptoms may include nausea, vomiting, and diarrhea. Management is primarily symptomatic and supportive. There is no specific antidote, and ceftriaxone is not significantly removed by hemodialysis or peritoneal dialysis.
Pregnancy & Lactation
Pregnancy Category B. Animal reproduction studies have not demonstrated a fetal risk. However, it should be used during pregnancy only if clearly needed after a thorough risk-benefit assessment by a physician. Ceftriaxone is excreted in breast milk in low concentrations; use with caution in breastfeeding mothers.
Side Effects
Contraindications
- Known hypersensitivity to ceftriaxone, any other cephalosporins, or any component of the formulation.
- Neonates (≤28 days) with hyperbilirubinemia, particularly premature neonates.
- Concomitant intravenous calcium administration in neonates.
Drug Interactions
Aminoglycosides
Synergistic effect against some bacteria, but solutions should not be mixed due to physical incompatibility.
Calcium-containing solutions
Concomitant use of ceftriaxone with intravenous calcium-containing solutions is contraindicated in neonates. In other age groups, a time interval should be observed between ceftriaxone and calcium administration.
Loop diuretics (e.g., Furosemide)
May increase the risk of nephrotoxicity with high doses of cephalosporins.
Oral anticoagulants (e.g., Warfarin)
May increase the anticoagulant effect and risk of bleeding. Close monitoring of coagulation parameters is advised.
Storage
Store the dry powder below 30°C, protected from light and moisture. After reconstitution, the solution should be used immediately. If not used immediately, store refrigerated (2-8°C) and use within 24 hours (for IV) or 6 hours (for IM). Do not freeze.
Overdose
In case of overdose, symptoms may include nausea, vomiting, and diarrhea. Management is primarily symptomatic and supportive. There is no specific antidote, and ceftriaxone is not significantly removed by hemodialysis or peritoneal dialysis.
Pregnancy & Lactation
Pregnancy Category B. Animal reproduction studies have not demonstrated a fetal risk. However, it should be used during pregnancy only if clearly needed after a thorough risk-benefit assessment by a physician. Ceftriaxone is excreted in breast milk in low concentrations; use with caution in breastfeeding mothers.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Generally 2-3 years from the date of manufacture when stored under recommended conditions. Refer to the specific product packaging for exact shelf life.
Availability
Pharmacies, Hospitals
Approval Status
Approved
Patent Status
Generic available
WHO Essential Medicine
YesClinical Trials
Ceftriaxone has undergone extensive clinical trials demonstrating its efficacy and safety in treating a wide range of bacterial infections across various patient populations, leading to its widespread approval and use globally.
Lab Monitoring
- Complete Blood Count (CBC) for prolonged therapy.
- Renal function tests (e.g., BUN, creatinine) in patients with pre-existing renal impairment or during prolonged treatment.
- Liver function tests (e.g., AST, ALT, bilirubin) in patients with pre-existing hepatic impairment.
- Coagulation parameters (e.g., PT/INR) in patients at risk of bleeding or concomitant use of anticoagulants.
Doctor Notes
- Confirm patient's allergy history, especially to penicillins and other cephalosporins, before administration.
- Monitor renal and hepatic function, especially in neonates, elderly, or patients with pre-existing conditions.
- Avoid concomitant intravenous calcium administration in neonates to prevent fatal precipitates.
- Educate patients on the importance of completing the full course of therapy.
Patient Guidelines
- It is crucial to complete the full prescribed course of treatment, even if symptoms improve, to prevent antibiotic resistance.
- Immediately report any signs of a severe allergic reaction (e.g., rash, itching, swelling, severe dizziness, trouble breathing).
- Inform your doctor about all other medications, including over-the-counter drugs, herbal supplements, and vitamins.
- Do not use this medicine without a prescription.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not double dose to make up for a missed one.
Driving Precautions
This medicine may cause dizziness in some individuals. If you experience dizziness, avoid driving or operating heavy machinery.
Lifestyle Advice
- Stay well-hydrated during the course of treatment.
- Maintain good personal hygiene to prevent further infections.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Kilbac Brand
Other medicines available under the same brand name
Kilbac
Tablet
Kilbac
Injection
Kilbac
Injection (for intravenous infusion)
Kilbac
Oral Suspension
Kilbac
Tablet